Physician profile
Carl G Albers
NPI 1982784047
$382,552.74
in general payments reported to CMS, 2019-2025
15 companies · $48K in 2025
The $48K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $12K · 2021: $47K · 2022: $45K · 2023: $25K · 2024: $134K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $179K · Travel and Lodging: $20K · Food and Beverage: $8,248 · Honoraria: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $179,087.50 |
| Travel and Lodging | $19,721.19 |
| Food and Beverage | $8,247.56 |
| Honoraria | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $97,547.08 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $92,063.08 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $84,593.14 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54,307.55 | 2019-2022 | |
| Allergan, INC. | $26,541.93 | 2019 | |
| Daiichi Sankyo INC. | $17,036.82 | 2019-2021 | |
| Abbvie INC. | $6,050.22 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $3,300.42 | 2019-2022 | |
| Medtronic, INC. | $315.95 | 2022-2025 | Gi Genius, Barrx |
| Cook Medical LLC | $187.99 | 2023 | Echotip, Fusion |
| Csa Medical, INC | $150.00 | 2019 | |
| Gilead Sciences, INC. | $121.63 | 2025 | Livdelzi |
| Lilly USA, LLC | $118.45 | 2025 | |
| Janssen Scientific Affairs, LLC | $114.52 | 2022 | |
| Capsovision, INC. | $103.96 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Albers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.